Abstract
Introduction:
Constipation is a common gastrointestinal disorder that can affect quality of life. Probiotics have garnered substantial attention for their potential to alleviate constipation. This study investigates the preventive effects of Bifidobacterium animalis subsp. lactis TG11 on loperamide-induced constipation in mice.
Methods:
Mice were randomly assigned to normal control (NC), constipation model (CM), and low, medium, and high-dose TG11 treatment groups (LG, MG, HG). From days 1–14, LG, MG, and HG groups received 106, 107, and 108 CFU/mouse of TG11, respectively, while NC and CM groups received saline. On day 14, all groups except NC were administered loperamide (4 mg/kg) orally to induce constipation. Fecal samples were collected for short-chain fatty acid and gut microbiota analyses. Following a 16-hour fasting period, various parameters were assessed on day 15, including intestinal motility, fecal water content, defecation status, gut peptide levels in blood, and mRNA expression levels of SCF and c-kit in colonic tissue.
Results:
TG11 significantly enhanced intestinal motility and maintained fecal water content. It normalized blood levels of MTL, SP, SS, ET-1, Gas, and VIP in constipated mice, promoted short-chain fatty acid production, and improved microbial metabolism. TG11 markedly upregulated mRNA expression of SCF and c-kit in colonic tissue. Metagenomic sequencing revealed that TG11 modulated gut microbiota composition, increasing the abundance of beneficial bacteria, particularly Muribaculum_sp. and uncultured_Duncaniella.
Discussion:
Bifidobacterium animalis subsp. lactis TG11 demonstrates efficacy in ameliorating constipation, potentially through modulation of the gut microbiota composition.
Introduction
Constipation is a prevalent disorder of the digestive system characterized by infrequent bowel movements, hard stools, and difficulty in stool passage. Chronic constipation can precipitate anorectal conditions and negatively affect mental health, thus significantly deteriorating life quality (). Common therapeutic strategies encompass dietary modifications, pharmacological interventions, topical lubricants, enemas, and surgical procedures, each associated with potential adverse effects ().
The gut microbiota consists of trillions of microorganisms, including bacteria, fungi, and viruses, plays integral roles in digestion, metabolism, immunity, gut barrier integrity, and vitamin production. These microorganisms generate short-chain fatty acids (SCFAs) through the fermentation of indigestible polysaccharides and resistant starch, thereby maintaining gut health (). Dysbiosis, marked by a decrease in beneficial bacteria and an increase in pathogenic counterparts, leads to reduced microbial diversity (). Research indicates a diminished prevalence of beneficial bacteria such as Bifidobacteria and Lactobacilli in patients with constipation, which compromises gut functionality ().
Gut peptides, synthesized by enteroendocrine cells, regulate various physiological processes including digestion and gut motility. Notable peptides include somatostatin (SS), motilin (MTL), gastrin (Gas), substance P (SP), and vasoactive intestinal peptide (VIP), which are pivotal in gastrointestinal function, gut mucosal barrier integrity, and immune modulation. In constipation, abnormal peptide levels can be observed in the bloodstream (; Xie et al., 2022). The SCF/c-kit signaling pathway is vital for the growth and survival of intestinal smooth muscle cells, enhancing gut contractility and motility. Conversely, its inhibition or dysfunction can diminish these cells or impair their function, leading to weakened peristalsis and constipation onset (; ).
Probiotic therapy offers a safer, milder alternative for managing constipation. Studies have demonstrated that probiotics influence constipation by altering gut transit time, stool frequency, and consistency, as well as microbiota composition (; ). Recent investigations have highlighted the role of specific Bifidobacteria strains in ameliorating constipation through various mechanisms, including dysbiosis correction, SCFA concentration increase, and neurotransmitter regulation (; ; ; Zhang et al., 2023a). For instance, strains such as Bifidobacterium G9-1 (BBG9-1) and Bifidobacterium animalis subsp. MN-Gup (MN-Gup) have shown promising results in both animal models and human trials.
In this study, we evaluate the protective effects of Bifidobacterium lactis TG11 against loperamide-induced constipation in mice, exploring the potential mechanisms through which TG11 mitigates constipation symptoms.
Materials and methods
Materials
Bifidobacterium lactis TG11, isolated from the intestines of healthy infants, is now maintained by Jinhua Galaxy Biotechnology Co., Ltd., located in China. The preservation is cataloged under the accession number 20230421003. The bacterial activity has been adjusted to 200 billion CFU/g.
Animal experiments
The research protocol for the animal studies received ethical approval from the Animal Welfare Ethics Review Committee of Heilongjiang University of Chinese Medicine (2024032915, Harbin, Heilongjiang, China). Male ICR mice, with a body mass range of 18–22 grams, were accommodated in a controlled laboratory environment and provided with standard care. The experimental process is detailed in Figure 1. The investigation commenced seven days following the adaptation period. Randomly assigned into five cohorts, the mice included a control cohort (NC), a constipation-induced model cohort (CM), and three treatment cohorts (TG11) with varying dosages: low (LG), medium (MG), and high (HG), each consisting of 20 animals. The trial was bifurcated into two phases: the TG11 treatment phase and the constipation induction phase, guided by the “Functional Assessment and Evaluation Protocols for Health Foods (2023 Edition)” for model design and loperamide dosing.
FIGURE 1
During the TG11 treatment phase (days 1–14), the NC and CM cohorts received saline solution, while the LG, MG, and HG cohorts were dosed with 10^6, 10^7, and 10^8 CFU/mouse of the bacterial preparation, respectively. On day 14, loperamide was orally administered to the CM cohort and all TG11 treatment cohorts at a rate of 4 mg/kg BW, with the NC cohort continuing to receive saline. The animals in all cohorts were subjected to a 16-h fasting period, maintaining access to water. On day 15, a solution of activated charcoal (5% charcoal and 10% arabic gum) at a volume of 10 ml/kg BW was administered. Ten mice from each group were closely monitored to document the time until the first instance of black stool was observed. Concurrently, an additional cohort of ten mice was assessed for gastrointestinal transit rate (GTR). Throughout the duration of the experiment, the mice were afforded unlimited access to both food and water, and their body weights were consistently recorded at regular intervals.
Sample collection and analysis
On the 15th day, fecal samples from the groups of mice were collected to measure their fecal water content (FWC). Upon the conclusion of the experiment, blood was drawn and serum was isolated using a refrigerated centrifuge set at 12,000 g for 10 min. This serum was then prepared for subsequent biochemical analyses. Samples from both the small intestine and colon were harvested for histological evaluation and real-time PCR analysis. Before oral administration of a solution of activated charcoal, Feces of mice were collected for short-chain fatty acid and metagenomic analysis, respectively.
Evaluation of time to first black stool and 5-h quantification of stool count and weight
Each mouse was housed in a clean cage and monitored immediately after drug administration. The time to first black stool occurrence was documented. Starting from the first black stool emergence (0 h), mice were continuously observed for 5 h, during which the number and weight of black stools were recorded.
Determination of fecal water content
The feces of mice in each group were collected for five consecutive hours starting from the first black stool, and wet weight and dry weight are calculated. Immediately after defecation, the feces were weighed while wet. The samples were then placed in an oven at 60°C for 12 h to determine their dry weight. The fecal water content (FWC) was calculated using the following formula:
Gastrointestinal transit rate measurement
Twenty-five minutes after administering activated carbon via gavage, the mice were euthanized and their entire intestinal tract was excised to assess the distance traveled by the charcoal. The Gastrointestinal Transit Rate (GTR) was calculated using the following formula:
Then, the thrust is converted to data according to the following formula: . In the formula, p represents the Gastrointestinal Transit Rate.
Small intestine histological examination
Approximately 0.5 cm segments of the small intestine were excised, cleansed with saline, and preserved in 4% paraformaldehyde. These tissue samples were processed for embedding in paraffin and sectioning within 72 h. Following this, they were typically stained using hematoxylin and eosin (H&E). For tissue analysis, an inverted fluorescence microscope (Nikon Eclipse E100, Japan) was employed to evaluate the architectural integrity of intestinal glands, the presence of lymphocyte infiltration, and overall colonic structural changes.
Biochemical marker quantification
Serum levels of motilin (MTL), substance P (SP), somatostatin (SS), endothelin-1 (ET-1), gastrin (Gas), and vasoactive intestinal peptide (VIP), were assayed using enzyme-linked immunosorbent assay (ELISA) kits provided by Elisa Biotech Co., Ltd. based in Shanghai, China.
mRNA expression analysis via RT-PCR
Total RNA was extracted from colon tissues using TRIzol reagent (Invitrogen, CA, USA). Subsequently, cDNA was synthesized from 1 μg of RNA as the template, utilizing the RevertAid First Strand cDNA Synthesis Kit (Invitrogen, CA, USA). Real-time PCR was performed on a Bio-Rad system (CA, USA), with GAPDH serving as the housekeeping gene to normalize the data. The primer sequences used in the analysis are summarized in Table 1. The mRNA expression levels were quantified using the 2–ΔΔCT method, which enables the assessment of fold changes in expression relative to the control group.
TABLE 1
| Gene name | Forward primer sequence | Reverse primer sequence |
| SCF | 5′-CATGGAAGAAAA CGCACCGA-3′ | 5′-CTTTCCCTTTCTCG GGACCT-3′ |
| c-kit | 5′-GACCCGACGCAA CTTCCTTA-3′ | 5′-TGAGCATCTTCA CGGCAACT-3′ |
| GAPDH | 5′-TGTGTCCGTCG TGGATCTGA-3′ | 5′-TTGCTGTTGAAG TCGCAGGAG-3′ |
Primer sequences used in this study.
Measurement of the short-chain fatty acids by UPLC-ESI-MS/MS
Pretreatment: Approximately 50 mg of fecal sample was weighed and mixed with 300 μL of acetonitrile solution (pre-cooled to 4°C) containing internal standards [2H9]-Pentanoic acid and [2H11]-Hexanoic Acid. The mixture was ground for 3 min at −20°C, followed by ultrasonic extraction in an ice-water bath for 10 min. The extract was centrifuged at 12,000 rpm for 10 min at 4°C, and the supernatant was collected. The supernatant was diluted 5-fold with acetonitrile solution containing the same internal standards.
Derivatization: An 80 μL aliquot of the diluted supernatant was sequentially mixed with 40 μL of 200 mM 3-NPH solution (prepared in 50% acetonitrile-water, v/v) and 40 μL of 120 mM EDC-6% pyridine solution (prepared in 50% acetonitrile-water, v/v). The reaction was carried out at 40°C for 30 min and subsequently cooled on ice for 1 min. The reaction mixture was filtered through a 0.22 μm microporous membrane to obtain the final derivative solution. The standard solutions were processed in the same manner as the samples.
UPLC-ESI-MS/MS Analysis: Chromatographic Conditions: The injection volume was 1 μL. The mobile phase consisted of solvent A (0.1% formic acid aqueous solution) and solvent B (acetonitrile/methanol, 2:1, v/v), with a flow rate of 0.4 mL/min. The gradient elution program was as follows: 0–2 min, 75% A; 2–11 min, 75% A → 45% A; 12–13 min, 25% A. Mass Spectrometry Conditions: Detection was performed in negative ion mode with a spray voltage of −4,500 V and an ion source temperature of 450°C. The column temperature was maintained at 40°C. Curtain gas pressure was set at 35 psi, while both nebulizing gas (Gas1) and auxiliary gas (Gas2) pressures were set at 50 psi. The collision-induced dissociation (CAD) parameter was set to medium.
Analysis of the microbial diversity
In the context of this study, a suite of 30 mouse samples was analyzed, yielding a robust dataset with a genomic range spanning 11.19 to 12.43 gigabases. The assemblage of these samples resulted in N50 contig lengths varying between 3,710 and 14,035 base pairs. A comprehensive gene catalog, devoid of redundancy, was constructed from these assemblies, comprising a total of 1,623,375 open reading frames (ORFs). The sample libraries were subjected to sequencing on the state-of-the-art Illumina Novaseq 6000 platform, generating 150-base-pair paired-end reads. Quality control and trimming were meticulously performed using Trimmomatic (version 0.36). Host genome alignment and read filtering were conducted with bowtie2 (version 2.2.9), preceding metagenome assembly via MEGAHIT (version 1.1.2), which led to the reported N50 contig statistics. ORF prediction was executed on the assembled contigs using prodigal (version 2.6.3), and the resulting amino acid sequences were derived. Redundancy was minimized through the application of CDHIT (version 4.5.7), establishing a non-redundant gene set. This set was then aligned to the NR database for taxonomic classification and functionally annotated against various databases using DIAMOND (version 0.9.7). Carbohydrate-active enzymes were identified by comparing the gene sets to the CAZy database with hmmscan (version 3.1), and their activities were approximated by summing gene abundances. Non-metric multidimensional scaling (NMDS) analysis, facilitated by R software (version 3.2.0), was employed to scrutinize the taxonomic and functional abundance profiles across the 30 samples.
Statistical evaluation methodology
Statistical analysis was performed using SPSS software (version 25.0). For normally distributed and homogeneous variance data, group differences were analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. For other non-normally distributed data, the Kruskal-Wallis test was used to assess differences between groups. Except for differences in species-level taxa within the gut microbiota, which were analyzed using the Kruskal-Wallis test due to their non-normal distribution, all other parameters, including constipation-related phenotypic parameters, gut peptides, cytokine levels, mRNA expression levels, and short-chain fatty acid concentrations, were analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. Graphs were generated using GraphPad Prism (version 9.5). Statistical significance was set at P < 0.05.
Results
TG11 prevented loperamide-induced constipation in mice
After administering TG11 for 14 days and a single dose of loperamide, the study assessed TG11’s effect on constipation. The findings revealed a significant decrease in the time to the first black stool (F = 22.59, P < 0.05), and increase in both fecal water content (F = 89.78, P < 0.05) and fecal quantity (F = 5.39, P < 0.05) in constipated mice, as depicted in Figures 2A–C. Additionally, the gastrointestinal transit rate (GTR) and 5-h Fecal Weight were markedly lower in the constipation model group (CM) compared to the normal control (NC). TG11 treatment raised GTR (F = 14.35, P < 0.05) and 5-h Fecal Weight (F = 34.17, P < 0.05) significantly (Figures 2D, E). These results confirm that TG11 effectively alleviates constipation in mice.
FIGURE 2
The histological assessment using Hematoxylin and Eosin staining revealed the impact of TG11 on the intestinal morphology in mice suffering from constipation. Loperamide treatment at low doses was observed to lead to the disappearance of intestinal glandular structures within the colonic lamina propria, coupled with a significant decrease in lymphocyte infiltration. In contrast, therapy with TG11 was able to maintain the architectural integrity of the intestinal glands in the lamina propria. Furthermore, TG11 exhibited an inhibitory effect on lymphocyte infiltration in the intestinal tract (as illustrated in Figure 2F). However, it should be noted that at low doses, the therapeutic effects of TG11 on preserving colonic structural integrity were less pronounced in mice with constipation.
Effect of TG11 on the levels of peptide hormones and cytokines in serum of mice
To evaluate the therapeutic potential of TG11 in modulating intestinal function through the regulation of critical neurotransmitters and hormones, we conducted quantification of mouse motilin (MTL), substance P (SP), somatostatin (SS), endothelin-1 (ET-1), gastrin (Gas), and vasoactive intestinal peptide (VIP). The constipation group exhibited significantly diminished levels of MTL, SP, and Gas, along with marked elevations in SS, ET-1, and VIP, as compared to the normal control group (Figures 3A–F). Administration of TG11, however, led to a notable restoration of MTL (F = 10.73, P < 0.05), SP (F = 35.93, P < 0.001), and Gas (F = 42.19, P < 0.001) to near physiological levels, concomitant with a significant reduction in SS (F = 6.23, P < 0.05), ET-1 (F = 114.93, P < 0.001) and VIP (F = 170.81, P < 0.001) concentrations. These data imply that TG11 may represent a promising intervention for the management of slow transit constipation, by re-equilibrating the intestinal neurotransmitter and hormone profile.
FIGURE 3
Effects of TG11 on mRNA levels of constipation-related intestinal factors
Studies have indicated that the mRNA expression levels of SCF and c-kit are associated with intestinal function. Constipation may be related to weakened intestinal motility and abnormal intestinal mucosal function. A decrease in the mRNA expression of SCF or c-kit could lead to insufficient activation of the c-kit receptor, thereby affecting intestinal motility and secretory functions, potentially exacerbating constipation symptoms. In mice with constipation, the mRNA expression levels of SCF and c-kit in the colon were significantly reduced. Compared to the control group (CM), treatment with various doses of TG11 increased the expression of SCF (F = 119.44, P < 0.001) and c-kit (F = 119.44, P < 0.001) by two to threefold, thereby alleviating the symptoms of constipation (Figures 4A, B).
FIGURE 4
Effect of TG11 on the short-chain fatty acids content in feces of mice
Utilizing Ultra-Performance Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry (UPLC-ESI-MS/MS), we investigated the impact of TG11 on the Short-Chain Fatty Acids (SCFAs) profile in fecal samples. The study comprised five cohorts: Control, Constipation Model (CM), and Low-, Medium-, and High-dose TG11 treatment groups. Our findings revealed a significant reduction in various SCFAs, including acetic (F = 77.58, P < 0.001), butyric (F = 86.49, P < 0.001), glutaric (F = 94.85, P < 0.001), isovaleric (F = 59.31, P < 0.001), malonic (F = 67.27, P < 0.001), and propionic acids (F = 14.25, P < 0.001), in the CM group compared to the Control. This observation suggests a substantial alteration in the metabolic functionality of the gut microbiota in the constipation model, resulting in diminished SCFA production. Intriguingly, we observed a dose-dependent restoration of SCFA levels with TG11 treatment. As the TG11 dosage increased, SCFA concentrations progressively recovered, converging toward those observed in the Control group. This trend implies a potential therapeutic effect of TG11 in normalizing gut microbiota metabolism and SCFA production in constipation (Figures 5A–F). In addition to the six SCFAs mentioned above, we also detected six other SCFAs, including pentanoic acid, hexanoic acid, 2,3-dihydroxy-3-methylbutanoic acid, lactic acid, malonic acid, and glutaric acid. However, these SCFAs did not show statistically significant differences between groups (P > 0.05).
FIGURE 5
Effect of TG11 on the structure of gut microbiota in mice
The NMDS analysis at the species level indicated that the NC group was distinct from the CM group, whereas the LG group showed a close relationship with the CM group. The MG and HG groups were also similar to the CM group, indicating that medium and high doses of TG11 can maintain a balanced state of the intestinal microbiota in mice (Figure 6A). We observed that higher doses of TG11 were linked to significant alterations in the composition of the gut microbiota, particularly at high doses (Figure 6B). At the species level, loperamide increased the abundance of Muribaculum_sp. (P < 0.05) and uncultured_Duncaniella (P < 0.05), while reducing the abundance of Muribaculum sp._NM65 B17, an effect that was reversed by TG11 treatment (Figures 6D–E).
FIGURE 6
TG11’s effect on mouse biological pathways
In our KEGG pathway analysis, we detected substantial disparities in a multitude of biochemical pathways between the TG11 intervention groups at varying doses, the disease model group, and the control. These pathways include, but are not limited to, fatty acid metabolism, drug metabolism, DNA repair, amino acid biosynthesis, and sulfur metabolism (Figure 7A). Notably, the high-dose TG11 intervention group (HG) exhibited pronounced alterations in pathways related to amino acid synthesis, neurogrowth factor signaling, and angiogenesis, implying a regulatory function of TG11 in these physiological processes. The moderate-dose (MG) and low-dose (LG) groups also revealed dose-dependent changes in select KEGG pathways, further highlighting the gradient of TG11’s impact (Figure 7B).
FIGURE 7
Discussion
Constipation, a gastrointestinal disorder that affects millions of people worldwide, severely reduces the quality of life of sufferers (). The condition is characterized by reduced bowel movements, hard stool consistency, and difficulty in defecation (). Currently, laxatives or softeners are commonly used for treatment, but their efficacy is limited and they come with side effects, leading to increased interest in the use of probiotics as a side-effect-free therapy (). Our research indicates that the probiotic strain TG11 effectively alleviates constipation induced by loperamide. Mechanistically, TG11 acts on multiple aspects including gastrointestinal peristalsis, intestinal morphology, and the composition of the gut microbiota.
The SCF/c-kit signaling pathway is involved in the regulation of intestinal peristalsis and mucosal function. The binding of the SCF (stem cell factor) ligand to the c-kit receptor activates downstream signaling pathways, modulating the release of gastrointestinal peptides and neurotransmitters (Zhang et al., 2024). In constipation, the mRNA expression of this pathway is downregulated, which suppresses intestinal peristalsis and fecal transit (). TG11 significantly increased the mRNA expression levels of SCF and c-kit in colonic tissue, The SCF/c-kit signaling pathway is not unique to smooth muscle cells. This pathway is also expressed in mast cells and interstitial cells of Cajal (; ). The changes in SCF and c-kit expression levels observed in this study, which used colonic tissue for measurement, may be a combined effect of various cell types. This is one of the limitations of our study. Future research could consider using cell-specific methods to clarify the responses of the SCF/c-kit signaling pathway to TG11 treatment in different cell types. Mice gastrin (MTL) can promote gastrointestinal peristalsis and gastric emptying (), while substance P (SP) is involved in pain signal transmission and intestinal peristalsis (), somatostatin (SS) inhibits gastrointestinal secretion and peristalsis (), endothelin-1 (ET-1) constricts blood vessels, regulates blood pressure, and participates in inflammatory responses (), gastrin (Gas) promotes gastric acid secretion and gastrointestinal peristalsis (), and vasoactive intestinal peptide (VIP) dilates blood vessels and regulates intestinal peristalsis and secretion (). After constipation, the altered levels of these peptides and cytokines lead to impaired intestinal function. Our study shows that TG11 treatment restores these indicators to near-physiological levels, and this restoration becomes more significant with increasing dosage. Amino acid metabolism is associated with intestinal peristalsis, gut microbiota balance, and intestinal osmotic pressure (; Wu et al., 2021). Branched-chain amino acids (BCAAs), after metabolism in the intestine, produce short-chain fatty acids that stimulate intestinal peristalsis and promote defecation (). Tyramine produced in the metabolic pathways of phenylalanine and tyrosine may affect the function of the intestinal nervous system, thereby influencing intestinal peristalsis (). KEGG analysis results suggest that amino acid metabolism may be an important pathway for the action of TG11, with the highest dose being the most significant.
We found that a dose of 4 mg/kg of loperamide was sufficient to induce constipation in mice, thus we adopted this dose, which is different from the commonly used dose of 10 mg/kg in other studies (; Zhang et al., 2023b; Zhang et al., 2023a). We utilized high-resolution metagenomic sequencing techniques to analyze the gut microbiota, a method that can directly identify bacteria to the species level (). Muribaculum can regulate the barrier function of the intestinal mucosa and immune response, while Duncaniella protects the intestinal barrier and is involved in the production of short-chain fatty acids (SCFAs) (; ). TG11 significantly increased the levels of short-chain fatty acids, including Acetic Acid, Butyric Acid, Glutaric acid, Isovaleric acid, Malonic acid, and Propionic acid. Acetic acid, propionic acid, butyric acid, and isovaleric acid are mainly produced by gut microbiota (; ), while glutaric acid and malonic acid are primarily derived from the tricarboxylic acid (TCA) cycle (). This suggests that the TG11 strain not only promotes the production of short-chain fatty acids by regulating gut microbiota but may also increase short-chain fatty acid content by influencing the host’s energy metabolism pathways. In our study, the abundance of Muribaculum_sp and Duncaniella was significantly elevated in the CM group, and TG11 treatment restored their abundance to the level of the NC group, indicating that these two bacteria may help the body against constipation. The abundance of Muribaculum_sp_NM65_B17 was reduced in the CM group but significantly increased in all dose treatment groups with TG11, suggesting that TG11 may contribute to the growth of this bacterium.
Recent studies have increasingly focused on Bifidobacterium in the field of constipation research. Similar to our study, used a loperamide-induced mouse model to investigate the therapeutic effects of NKU FB3-14 on constipation. Both studies demonstrated the ability to modulate intestinal peptides including MLT, SS, and VIP. NKU FB3-14 did not exhibit a regulatory effect on SP levels. Both NKU FB3-14 and TG11 significantly increased the butyrate content in the feces of constipated mice. Moreover, TG11 also elevated the levels of acetate, propionate, isovaleric acid, glutaric acid, and malonic acid in the feces. In the constipation model established by , the abundance of Ruminococcaceae and Olsenella decreased, whereas in our model, the abundance of Muribaculum sp. and Duncaniella increased. This discrepancy could be attributed to several factors. The animal strains used were different: we used ICR mice, while used BALB/c mice. Different mouse strains may respond differently to the same treatment. The influence on SP levels suggests that the effect of NKU FB3-14 on intestinal motility may be more pronounced in functional constipation rather than organic lesions (). Compared to NKU FB3-14, TG11 exerted a broader influence on SCFAs, indicating that TG11 might promote the growth of gut microbiota that produce SCFAs. In the study by , Bifidobacterium longum effectively alleviated constipation in mice induced by loperamide. Similar to TG11, B. longum significantly improved all constipation-related indicators but did not ameliorate MTL, SP, SS, and VIP levels. Moreover, B. longum only increased the acetate level in feces, differing from the broad effects of TG11 on SCFAs. The differences might stem from the mechanism by which B. longum alleviates constipation, which does not rely on gastrointestinal hormones. Additionally, used BALB/c mice, differing from the ICR strain used in our study. Comparing these two bifidobacteria, we observed that although certain bifidobacteria have the ability to alleviate constipation, their mechanisms of action and effective doses vary. This highlights the need to select suitable probiotics for intervention based on the phenotype of constipation.
A 2006 clinical study confirmed W11’s efficacy in alleviating constipation (). Subsequently, through bioinformatics analysis and cultivation experiments, revealed that W11 metabolizes arabinomannan to produce SCFAs, thereby improving intestinal motility–a process closely linked to abfA and abfB gene expression. In a randomized, triple-blind, placebo-controlled clinical trial, found that while HN019 did not significantly increase complete spontaneous bowel movement (CSBM) frequency, it significantly improved abdominal pain and bloating. This suggests that although certain probiotics show promising results in animal studies, further clinical validation is essential.
These findings provide a new perspective on the treatment of constipation, and probiotic therapy holds the promise of improving the quality of life for constipation sufferers. Subsequent studies should further develop the application of probiotics in the treatment of constipation, providing a more solid scientific basis for clinical practice.
Conclusion
This study investigates the ameliorative effects of the probiotic Bifidobacterium animalis subsp. lactis TG11 on loperamide-induced constipation in mice, alongside the underlying mechanisms involved. Our findings reveal that TG11 significantly alleviates constipation symptoms, evidenced by a reduction in defecation time, an increase in fecal water content and quantity, and an enhancement in intestinal transit rate. Mechanistic investigations suggest that TG11 exerts its beneficial effects through multiple pathways: (1) modulating the levels of gut-related peptide hormones and cytokines; (2) upregulating the mRNA expression of SCF and c-kit in colonic tissues; (3) restoring gut microbiota balance; (4) regulating amino acid metabolism across various biological pathways. These insights provide a robust scientific foundation for the development of novel probiotic formulations aimed at treating constipation.
Statements
Data availability statement
The original contributions presented in this study are publicly available. This data can be found here: https://www.ncbi.nlm.nih.gov/sra/PRJNA1207417. The object IDs and corresponding URLs can be found in Supplementary Data Sheet 1.
Ethics statement
The animal study was approved by the Animal Welfare Ethics Review Committee of Heilongjiang University of Chinese Medicine. The study was conducted in accordance with the local legislation and institutional requirements.
Author contributions
WM: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft. YZ: Conceptualization, Data curation, Investigation, Methodology, Visualization, Writing – original draft. YL: Data curation, Investigation, Validation, Writing – review and editing. YW: Investigation, Validation, Visualization, Writing – review and editing. SY: Investigation, Validation, Writing – review and editing. LH: Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review and editing.
Funding
The authors declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Natural Science Foundation of Heilongjiang Province of China (No. LH2022H086), the Heilongjiang Provincial Program for Supporting Young Scholars of Undergraduate Universities (YQJH2023152), the Heilongjiang Provincial Postdoctoral Science Foundation (LBH-Q13161), Heilongjiang Province Touyan Team, and the Key Laboratory of the Ministry of Education—North Medicine Fundamental and Applied Research Open Fund.
Acknowledgments
We would like to express our sincere gratitude to the Natural Science Foundation of Heilongjiang Province of China (LH2019H106, LH2022H086) for supporting this research. We also extend our thanks to the Heilongjiang Provincial Undergraduate Universities “Outstanding Young Teachers Basic Research Support Program” (YQJH2023152), the Heilongjiang Province Postdoctoral Research Start-up Fund (LBH-Q13161), and the Heilongjiang Province Touyan Team for their invaluable support. Special acknowledgment is given to the Key Laboratory of the Ministry of Education—North Medicine Fundamental and Applied Research for providing an open fund that contributed to the successful completion of this work. Their generous funding and support have played an integral role in advancing our research, and we are deeply appreciative of their contributions.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The authors declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2025.1525887/full#supplementary-material
References
1
AmentaM.CascioM. T. (2006). Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight).Acta biomed.77157–162.
2
ArnoldP. K.FinleyL. W. S. (2023). Regulation and function of the mammalian tricarboxylic acid cycle.J. Biol. Chem.299:102838. 10.1016/j.jbc.2022.102838
3
BarberioB.JudgeC.SavarinoE. V. (2021). Global prevalence of functional constipation according to the Rome criteria: A systematic review and meta-analysis.Lancet Gastroenterol. Hepatol.6638–648. 10.1016/S2468-1253(21)00111-4
4
BharuchaA. E.LacyB. E. (2020). Mechanisms, evaluation, and management of chronic constipation.Gastroenterology1581232–1249.e3. 10.1053/j.gastro.2019.12.034
5
ChaiY.HuangY.TangH. (2017). Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome.Exp. Therapeutic Med.131187–1193. 10.3892/etm.2017.4133
6
ChangC. S.LiaoY. C.HuangC. T. (2021). Identification of a gut microbiota member that ameliorates DSS-induced colitis in intestinal barrier enhanced Dusp6-deficient mice.Cell Rep.37:110016. 10.1016/j.celrep.2021.110016
7
ChengJ.GaoC.Ala-JaakkolaR. A. (2024). Eight-week supplementation with Bifidobacterium lactis HN019 and functional constipation: A randomized clinical trial.JAMA Netw. Open7:e2436888. 10.1001/jamanetworkopen.2024.36888
8
ChoiB. H.HyunS.KooS. H. (2024). The role of BCAA metabolism in metabolic health and disease.Exp. Mol. Med.561552–1559. 10.1038/s12276-024-01263-6
9
ChoiY. J.KimJ. E.LeeS. J. (2021). Dysbiosis of fecal microbiota from complement 3 knockout mice with constipation phenotypes contributes to development of defecation delay.Front. Physiol.12:650789. 10.3389/fphys.2021.650789
10
De MartinoM. C.HoflandL. J.LambertsS. W. (2010). Somatostatin and somatostatin receptors: From basic concepts to clinical applications.Prog. Brain Res.182255–280. 10.1016/S0079-6123(10)82011-4
11
DeGruttolaA. K.LowD.MizoguchiA. (2016). Current understanding of dysbiosis in disease in human and animal models.Inflamm. Bowel Dis.221137–1150. 10.1097/MIB.0000000000000750
12
Di PierroF.ZerbinatiN.CazzanigaM. (2024). The anti-constipation effect of Bifidobacterium Longum W11 is likely due to a key genetic factor governing arabinan utilization.Microorganisms12:1626. 10.3390/microorganisms12081626
13
DingG.YangX.LiY. (2024). Gut microbiota regulates gut homeostasis, mucosal immunity and influences immune-related diseases.Mol. Cell Biochem.10.1007/s11010-024-05077-yOnline ahead of print.
14
DuanS.RicoK.MerchantJ. L. (2021). Gastrin: From physiology to gastrointestinal malignancies.Function (Oxford, England)3:zqab062. 10.1093/function/zqab062
15
FernstromJ. D.FernstromM. H. (2007). Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain.J. Nutr.137(6 Suppl. 1), 1539S–1548S. 10.1093/jn/137.6.1539S
16
FuH.FanD.WangJ. (2024). Bifidobacterium longum subsp. infantis NKU FB3-14 attenuates loperamide-induced constipation through regulation of gut microbiota.Food Quality Saf. [Preprint]. 10.1093/fqsafe/fyae043
17
GribbleF. M.ReimannF. (2019). Function and mechanisms of enteroendocrine cells and gut hormones in metabolism.Nat. Rev. Endocrinol.15226–237. 10.1038/s41574-019-0168-8
18
HaysK. E.PfaffingerJ. M.RyznarR. (2024). The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease.Gut Microbes16:2393270. 10.1080/19490976.2024.2393270
19
HeidelbaughJ.Martinez, de AndinoN.PinelesD. (2021). Diagnosing constipation spectrum disorders in a primary care setting.J. Clin. Med.10:1092. 10.3390/jcm10051092
20
HoudeM.DesbiensL.D’Orléans-JusteP. (2016). Endothelin-1: Biosynthesis, signaling and vasoreactivity.Adv. Pharmacol (San Diego, Calif).77143–175. 10.1016/bs.apha.2016.05.002
21
IwasakiM.AkibaY.KaunitzJ. D. (2019). Recent advances in vasoactive intestinal peptide physiology and pathophysiology: Focus on the gastrointestinal system.F1000Res8:F1000FacultyRev–1629. 10.12688/f1000research.18039.1
22
JangY. J.MoonJ. S.KimJ. E. (2024). Blending three probiotics alleviates loperamide-induced constipation in Sprague-Dawley (SD) rats.Food Sci. Anim. Resour.44119–131. 10.5851/kosfa.2023.e61
23
KimN. Y.KimK. A.YangH. J. (2023). Comparison of the laxative effects of Korean Gochujang containing different microbiota on loperamide-induced constipation in ICR mice.Food Funct.147615–7630. 10.1039/d2fo04111a
24
LacyB. E.SheaE. P.ManuelM. (2021). Lessons learned: Chronic idiopathic constipation patient experiences with over-the-counter medications.PLoS One16:e0243318. 10.1371/journal.pone.0243318
25
LennartssonJ.RönnstrandL. (2012). Stem cell factor receptor/c-Kit: From basic science to clinical implications.Physiol. Rev.921619–1649. 10.1152/physrev.00046.2011
26
LiT. T.ChenX.HuoD. (2024). Microbiota metabolism of intestinal amino acids impacts host nutrient homeostasis and physiology.Cell Host Microbe32661–675.e10. 10.1016/j.chom.2024.04.004
27
LiuY.YangL.BiC. (2021). Nostoc sphaeroides Kütz polysaccharide improved constipation and promoted intestinal motility in rats.Evid. Based Complement Alternat. Med.2021:5596531. 10.1155/2021/5596531
28
MakizakiY.UemotoT.YokotaH. (2021). Improvement of loperamide-induced slow transit constipation by Bifidobacterium bifidum G9-1 is mediated by the correction of butyrate production and neurotransmitter profile due to improvement in dysbiosis.PLoS One16:e0248584. 10.1371/journal.pone.0248584
29
MullerE.AlgaviY. M.BorensteinE. (2021). A meta-analysis study of the robustness and universality of gut microbiome-metabolome associations.Microbiome9:203. 10.1186/s40168-021-01149-z
30
NagpalR.KurakawaT.TsujiH. (2017). Evolution of gut Bifidobacterium population in healthy Japanese infants over the first three years of life: A quantitative assessment.Sci. Rep.7:10097. 10.1038/s41598-017-10711-5
31
NortonJ. A.FosterD. S.ItoT. (2018). Gastrinomas: Medical or surgical treatment.Endocrinol. Metab. Clin. North Am.47577–601. 10.1016/j.ecl.2018.04.009
32
RayA. P.CheboluS.RamirezJ. (2009). Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting.Behav. Neurosci.123701–706. 10.1037/a0015733
33
RönnstrandL. (2004). Signal transduction via the stem cell factor receptor/c-Kit.Cell. Mol. Life Sci.612535–2548. 10.1007/s00018-004-4189-6
34
SharmaA.RaoS. S. C.KearnsK. (2021). Review article: Diagnosis, management and patient perspectives of the spectrum of constipation disorders.Aliment Pharmacol. Ther.531250–1267. 10.1111/apt.16369
35
TangT.WangJ.JiangY. (2022). Bifidobacterium lactis TY-S01 prevents loperamide-induced constipation by modulating gut microbiota and its metabolites in mice.Front. Nutr.9:890314. 10.3389/fnut.2022.890314
36
TegegneB. A.KebedeB. (2022). Probiotics, their prophylactic and therapeutic applications in human health development: A review of the literature.Heliyon8:e09725. 10.1016/j.heliyon.2022.e09725
37
WangL.ChaiM.WangJ. (2022). Bifidobacterium longum relieves constipation by regulating the intestinal barrier of mice.Food Function135037–5049. 10.1039/d1fo04151g
38
WangR.SunJ.LiG. (2021). Effect of Bifidobacterium animalis subsp. lactis MN-Gup on constipation and the composition of gut microbiota.Benef. Microbes1231–42. 10.3920/BM2020.0023
39
WangY.GaoP.LiC. (2024). High-fidelity gut metagenome: A new insight of identification of functional probiotics. J. Integr. Agric. [Preprint]. 10.1016/j.jia.2024.05.011
40
WestfallS.CarracciF.EstillM. (2021). Optimization of probiotic therapeutics using machine learning in an artificial human gastrointestinal tract.Sci. Rep.11:1067. 10.1038/s41598-020-79947-y
41
WuL.TangZ.ChenH. (2021). Mutual interaction between gut microbiota and protein/amino acid metabolism for host mucosal immunity and health.Anim. Nutr.711–16. 10.1016/j.aninu.2020.11.003
42
XieX.GengC.LiX. (2022). Roles of gastrointestinal polypeptides in intestinal barrier regulation.Peptides151:170753. 10.1016/j.peptides.2022.170753
43
ZhangC.WangL.LiuX. (2023a). The different ways multi-strain probiotics with different ratios of Bifidobacterium and Lactobacillus relieve constipation induced by loperamide in mice.Nutrients15:4230. 10.3390/nu15194230
44
ZhangC.YuL.MaC. (2023b). A key genetic factor governing arabinan utilization in the gut microbiome alleviates constipation.Cell Host Microbe311989–2006.e8. 10.1016/j.chom.2023.10.011
45
ZhangQ.LiG.ZhaoW. (2024). Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: A randomized placebo-controlled clinical trial.Nat. Commun.15:227. 10.1038/s41467-024-36748-7
Summary
Keywords
probiotics, constipation, gut microbiota, gut peptides, SCF/c-kit
Citation
Ma W, Zhao Y, Liu Y, Wang Y, Yu S and Huang L (2025) Bifidobacterium animalis subsp. lactis TG11 ameliorates loperamide-induced constipation in mice by modulating gut microbiota. Front. Microbiol. 16:1525887. doi: 10.3389/fmicb.2025.1525887
Received
12 November 2024
Accepted
10 January 2025
Published
29 January 2025
Volume
16 - 2025
Edited by
Yu Pi, Chinese Academy of Agricultural Sciences, China
Reviewed by
Jing Liu, Agricultural Research Service (USDA), United States
Lee Tran, Mayo Clinic Arizona, United States
Updates
Copyright
© 2025 Ma, Zhao, Liu, Wang, Yu and Huang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lili Huang, huanglili@hljucm.edu.cn
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.